Instilación intrapleural de activador tisular de plasminógeno y de deoxirribonucleasa recombinante humana en el empiema pleural. Visits. Download PDF. Se colocó un catéter en el extremo aórtico de la fístula y se instauró, a su través, tratamiento con activador recombinante tisular del plasminógeno (r-TPA) en. activator in vascular warning syndromesTrombólisis intravenosa con activador tisular del plasminógeno recombinante en los síndromes de alarma vascular☆.
|Published (Last):||11 May 2011|
|PDF File Size:||10.45 Mb|
|ePub File Size:||10.84 Mb|
|Price:||Free* [*Free Regsitration Required]|
This item has received.
There was a problem providing the content you requested
To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior. From Monday to Friday from 9 a. Print Send to a friend Export reference Mendeley Statistics.
Intracardiac thrombi; Neonatal thrombolysis; Recombinant tissue plasminogen activator. March Pages ee24 Pages You can change the settings or obtain more information by clicking here. Si continua navegando, consideramos que acepta su uso.
Continuing navigation will be considered as acceptance of this use. SRJ is a prestige metric based on the idea that not all citations are the same. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up. Three patients received low molecular weight heparin prior to using rTPA. The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them.
Activador del plasminógeno tisular recombinante en el manejo de trombos cardiacos en recién nacidos
There were no deaths or embolism. Nine issues are published each year, including mostly originals, reviews and consensus documents. Previous article Next article. The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant tissue plasminogen activator rTPA has been used as an alternative to heparin in life threatening giant thrombus and embolization. CiteScore measures average citations received per document published.
The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days.
Subscribe to our Newsletter. In 4 patients complete resolution of the thrombus was achieved in a mean of 3. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns. Are you a health professional able to prescribe or dispense drugs?
The patients included 4 males with a mean weight of gr.
SJR uses a similar algorithm as the Google page rank; tisula provides a quantitative and qualitative measure of the journal’s impact. Subscriber If you already have your login data, please click here. The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns.
They received between 1 to 5 cycles with rTPA.